- Home
- LILA vs ORKA Comparison
LILA vs ORKA Comparison
Compare LILA & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILA | ORKA |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LILA | ORKA |
|---|---|---|
| Price | $7.99 | $31.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $9.75 | ★ $48.20 |
| AVG Volume (30 Days) | 343.2K | ★ 656.5K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,433,000,000.00 | N/A |
| Revenue This Year | $1.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.26 | $5.49 |
| 52 Week High | $9.04 | $32.28 |
Technical Indicators
Market Signals| Indicator | LILA | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 40.31 | 60.77 |
| Support Level | $8.29 | $27.84 |
| Resistance Level | $8.75 | $31.35 |
| Average True Range (ATR) | 0.25 | 1.96 |
| MACD | -0.09 | -0.21 |
| Stochastic Oscillator | 1.83 | 89.55 |
Price Performance
Historical ComparisonAbout LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.